



Short Curriculum vitae Wim E. Hennink

Professor Wim Hennink studied molecular sciences at the Agricultural University of Wageningen, The Netherlands. He graduated in 1981. He obtained his Ph.D. in 1985 at the Twente University of Technology. From April 1985 until November 1989 he worked as a research scientist at the Plastic and Rubber Institute TNO in Delft, the Netherlands. From December 1989 until July 1992 he worked as a development engineer within the R&D Department of Fasson in Leiden, the Netherlands. In July 1992 he took up his present position. From 1996 on he is Head of the Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University. From 1997 until 2005 he was European Editor of the Journal of Controlled Release. His main research interests are in the field of polymeric drug delivery systems.

Appendix: List of publication

List of publications, Wim Hennink, January 2005.

1. Van Dedem G, Van Houdenhoven F, and Hennink WE. The USP heparin assay fact and artefact. In: Chemistry and Biology of Heparin (ed. R.L. Lundblad, W.V. Brown, K.G. Mann and H.R. Roberts), Elsevier North Holland Inc., 19-28, 1981.
2. Trummer J, Hennink WE, and Van der Plas HC. Oxidation of 7-alkylpteridin-4-ones to 7-alkylfluorazines. *J. Appl. Biochem.* 4, 263-270, 1982.
3. Hennink WE, Feijen J, Ebert CD, and Kim SW. Covalently bound conjugates of albumin and heparin: synthesis, fractionation and characterization. *Thromb. Res.* 29, 1-13, 1983.
4. Feijen J, and Hennink WE. Conjugates of anticoagulant and protein. *Eur. Pat. Appl.* EP 81853, 1983.
5. Hennink WE, Dost L, Feijen J, and Kim SW. Interaction of albumin-heparin conjugate preadsorbed surfaces with blood. *Transactions American Society For Artificial Internal Organs* 29, 200-205, 1983.
6. Hennink WE, Ebert CD, Kim SW, Breenhaar W, Bantjes A, and Feijen J. Interaction of antithrombin III with preadsorbed albumin-heparin conjugate. *Biomaterials* 5, 264-268, 1984.
7. Hennink WE, Kim SW, and Feijen J. Inhibition of surface induced coagulation by preadsorption of albumin-heparin conjugates. *J. Biomed. Mater. Res.* 18, 911-926, 1984.
8. Hennink WE, Dost L, Kim SW, Van Aken WG, and Feijen J. Blood compatibility of albumin-heparin conjugate treated surfaces. *Biomaterials in Artificial Organs* (ed. Paul, J.P., Gaylor, J.D.S., Courtney, J.M. and Gilchrist, T.), 203-213, 1983.
9. Hennink WE, Klerx JPAM, Van Dijk H, and Feijen J. Complement inhibitory and anticoagulant activities of fractionated heparins. *Thromb. Res.* 36, 281-292, 1984.
10. Hennink WE. Albumin-heparin conjugate as a coating for biomaterials. Thesis University of Twente, Enschede, The Netherlands, 1985.
11. Hennink WE, Knipsma AJK, Engbers GHM, Dost L, and Feijen J. Is the use of low molecular weight heparin in blood compatible surface coatings advantageous over that of nonfractionated heparin? *Proceedings of the Vth International Conference: Polymers in Medicine and Surgery*, Page 7/1-7/11, 1986.
12. Engbers GHM, Dost L, Hennink WE, Aarts PAMM, Sixma JJ, and Feijen J. Platelet adhesion studies onto albumin-heparin conjugate coated catheters. *Life Support Syst.* 4, 416-418, 1986.
13. Hennink WE, Van den Berg JWA, and Feijen J. Standardization of heparins by means of high performance liquid chromatography equipped with a low angle laser light scattering detector. *Thromb. Res.* 45, 463-475, 1987.
14. Engbers GHM, Dost L, Hennink WE, Aarts PAMM, Sixma JJ, and Feijen J. An in vitro study of the adhesion of blood platelets onto vascular catheters. Part I. *J. Biomed. Mater. Res.* 21, 613-627, 1987.
15. Hennink WE. UV-polymerisatie: principes en mogelijkheden. *Verfkronek* 61, 260-263, 1988.
16. Huizer L, and Hennink WE. Moisture-permeable polymer network for coating/impregnating. *Eur. Pat. Appl.* EP 88-201363, 1989.
17. Smit CN, Hennink WE, De Ruiter B, Luiken AH, Marsman MPW, and Bouwma J. Radiation cured halogen free flame-retardant coating. *RadTech* 90, 144-153, 1990.
18. Daurloo MJM, Bohlken S, Kop W, Lerk CF, Hennink WE, Bartelink H, and Begg AC. Intratumoural administration of cisplatin in slow-release devices. *Cancer Chemother. Pharmacol.* 27, 135-140, 1990.
19. Hennink WE, and Wiltink Th. Cationically hardenable coating compositions, and their application as release coatings. *Neth. Pat. Appl.* NL 9100226, 1992.
20. Borchert JCH, Van Soest MJ, and Hennink WE. Controlled release of proteins from hydrogels. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 21, 306-307, 1994.
21. Wolthuis WNE, Van Hooft BJM, and Hennink WE. Synthesis and characterization of poly(ethylene glycol) poly-L-lactide block copolymers. *Proc. 3rd Eur. Symp. on Controlled Drug Delivery*, 271-276, 1994.
22. De Smedt SC, Lauwers A, Demeester J, Van Steenberghe MJ, Hennink WE, and Roefs SPFM. Characterization of the network structure of dextran glycidyl methacrylate hydrogels by studying the rheological and swelling behavior. *Macromolecules* 28, 3082-3088, 1995.
23. Van Dijk-Wolthuis WNE, Franssen O, Talsma H, Van Steenberghe MJ, Kettenes-van den Bosch JJ, and Hennink WE. Synthesis, characterization and polymerization of

- glycidyl methacrylate derivarized dextran. *Macromolecules* 28, 6317-6322, 1995.
24. Hennink WE, Franssen O, Overbeek AY, Van Steenberg MJ, and Talsma H. Enzymatic Degradation of dextran hydrogels. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 22, 23-24, 1995.
 25. Hennink WE, Talsma H, Borchert JCH, De Smedt SC, and Demeester J. Controlled release of proteins from dextran hydrogels. *J. Control. Release* 39, 47-53, 1996.
 26. Cheng JY, Van de Wetering P, Talsma H, Crommelin DJA, and Hennink WE. Effect of size and serum proteins on transfection efficiency of poly((2-dimethylamino)ethylmethacrylate)-plasmid nanoparticles. *Pharm. Res.* 13, 1038-1042, 1996.
 27. Van Dijk-Wolthuis WNE, Tsang SKY, and Hennink WE. Biodegradable dextran hydrogels. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 23, 755-756, 1996.
 28. Hennink WE, Feijen J, and Crommelin DJA. Gecontroleerde en gerichte afgifte geneesmiddelen; 'slimme' verpakking wijst de weg en stuurt dosering. *Chemisch Magazine*, oktober 1996, 413-415.
 29. Franssen O, Vos OP, and Hennink WE. Delayed release of a model protein from enzymatically degrading dextran hydrogels. *J. Control. Release* 44, 237-245, 1997.
 30. Hennink WE, Franssen O, Van Dijk-Wolthuis WNE, and Talsma H. Dextran hydrogels for the controlled release of proteins. *J. Control. Release* 48, 107-114, 1997.
 31. Van de Wetering P, Cheng JY, Talsma H, and Hennink WE. Relation between the transfection efficiency and cytotoxicity of poly((2-dimethylamino)-ethyl methacrylate)-plasmid complexes. *J. Control. Release* 49, 59-71, 1997.
 32. Van der Voort Maarschalk K, Zuurman K, Van Steenberg MJ, Hennink WE, Vromans H, Bolhuis GK, and Lerk CF. Effect of compaction temperature on consolidation of amorphous copolymers with different glass transition temperatures. *Pharm. Res.* 14, 415-419, 1997.
 33. Van Dijk-Wolthuis WNE, Van Steenberg MJ, Underberg WJM, and Hennink WE. Degradation kinetics of methacrylated dextrans in aqueous solution. *J. Pharm. Sci.* 86, 413-417, 1997.
 34. Schlicher BJAM, Postma N, Zuidema J, Talsma H, and Hennink WE. Preparation and characterization of poly(D,L-lactic-co-glycolic acid) microspheres containing desferrioxamine. *Int. J. Pharm.* 153, 235-245, 1997.
 35. Van Dijk-Wolthuis WNE, Kettenes-van den Bosch JJ, Van der Kerk-van Hoof A, and Hennink WE. Reaction of dextran with glycidyl methacrylate: an unexpected transesterification. *Macromolecules* 30, 3411-3413, 1997.
 36. Van Dijk-Wolthuis WNE, Tsang SKY, Kettenes-van den Bosch JJ, and Hennink WE. A new class of polymerizable dextrans with hydrolyzable groups: hydroxyethyl methacrylated dextran with and without oligolactate spacer. *Polymer* 38, 6233-6242, 1997.
 37. Van Dijk-Wolthuis WNE, Van de Water L, Van de Wetering P, Van Steenberg MJ, Kettenes-van den Bosch JJ, Schuyt PJW, and Hennink WE. Synthesis and characterization of poly-L-lysine with controlled low molecular weight. *Macromol. Chem. Phys.* 198, 3893-3907, 1997.
 38. Van Dijk-Wolthuis WNE, Tsang SKY, Van Steenberg MJ, Hoozeboom C, and Hennink WE. Degradation and release behaviour of dextran based hydrogels. *Macromolecules* 30, 4639-4645, 1997.
 39. De Smedt SC, Meyvis TKL, Demeester J, Van Oostveldt P, Blonk JCG, and Hennink WE. The diffusion of macromolecules in dextran glycidyl methacrylate solutions and gels as studied by confocal laser microscopy. *Macromolecules* 30, 4863-4870, 1997.
 40. Hennink WE, Feijen J, and Crommelin DJA. 'Routeplanner' helpt geneesmiddel ziekte plaats te vinden. *Liposomen die cytotarica bevatten. Conceptuur* 11, 6-8, 1997.
 41. Talsma H, Cheng JY, Lehrmann H, Malgorzata K, Ogris M, Hennink WE, Corton M, and Wagner E. Stabilization of gene delivery systems by freeze-drying. *Int. J. Pharm.* 157, 233-238, 1997.
 42. Franssen O, Van Ooijen RD, De Boer D, Maes RAA, Herron JN, and Hennink WE. Enzymatic degradation of methacrylated dextrans. *Macromolecules* 30, 7408-7413, 1997.
 43. Cheng JY, Van de Wetering P, Talsma H, Crommelin DJA, and Hennink WE. Freeze-drying of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems. *Pharm. Res.* 14, 1837-1840, 1997.
 44. Hennink WE, and Van de Wetering P. Cationic polyacrylates and poly(alkyl) acrylates and acrylamides for use as carriers of nucleic acid in the transformation of

- animal cells. PCT Int. Appl. WO 9715680, 1997.
45. Hennink WE, and Talsma H. Pharmaceutical applications of gelatin. *Industrial Proteins* 4, 5-6, 1997.
46. Hennink WE, and Bout A. A transfection system using poly(organo)phosphazenes complexes with nucleic acids. PCT Int. Appl. WO 9707226, 1997.
47. Van de Wetering P, Cherng JY, Gutierrez-Camacho P, Talsma H, and Hennink WE. Relation between the transfection efficiency and cytotoxicity of poly(DMAEMA)/plasmid complexes. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 24, 655-656, 1997.
48. Van de Wetering P, Cherng JY, Talsma H, Crommelin DJA, and Hennink WE. 2-(Dimethylaminoethyl) methacrylate based polymers and copolymers as gene delivery agents. *J. Control. Release* 53, 145-155, 1998.
49. Goddemaod JH, and Hennink WE. Polyetherester copolymers as drug delivery matrices. PCT Int. Appl. WO 9806439, 1998.
50. Stenakes RJJ, Franssen O, van Bommel EMG, Crommelin DJA, and Hennink WE. The preparation of dextran microspheres in an all-aqueous system: effect of the formulation parameters on particle characteristics. *Pharm. Res.* 15, 557-561, 1998.
51. Hennink WE, and Van Dijk-Wolthuis WNE. Hydrolyzable hydrogels comprising two interpenetrating polymer networks for controlled release. PCT Int. Appl. WO 9800170, 1998.
52. Franssen O, and Hennink WE. A Novel preparation method for polymeric microparticles without the use of organic solvents. *Int. J. Pharm.* 168, 1-7, 1998.
53. Franssen O, and Hennink WE. Preparation of dextran microspheres by in all-aqueous system. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 25, 232-233, 1998.
54. Meyvis TKL, van Oostveldt P, Hennink WE, and Deemeester J. Correlation between rheological characteristics of enzymatically degrading dextran glycidyl methacrylate gels and the mobility of macromolecules inside these gels. In: *Chemical and Physical Networks, Formation and control of properties*, K. to Nijenhuis and W.J. Mijls, ed., John Wiley and sons, 1998, 527-535.
55. De Jong SJ, Van Dijk-Wolthuis WNE, Komenes-van den Bosch JJ, Schuyt PJW, and Hennink WE. Monodisperse enantiomeric lactic acid oligomers: preparation, characterization and stereocomplex formation. *Macromolecules* 31, 6397-6402, 1998.
56. Van de Wetering P, Zuidam NJ, Van Steenberg MJ, Van der Houwen OAGJ, Underberg WJM, and Hennink WE. A mechanistic study of the hydrolytic stability of poly(2-(dimethylaminoethyl methacrylate). *Macromolecules* 31, 8063-8068, 1998.
57. Hennink WE, and Franssen O. Process for the preparation of a controlled release system. WO9822093, 1998.
58. Van de Weert M, Van 't Hof R, Hennink WE, and Crommelin DJA. Stability of pharmaceutical proteins in particulate carriers. In: *Peptide and Protein Drug Delivery* (Froljaer S, Christrup L and Krogsgaard-Larsen P, Eds.), Munksgaard, Copenhagen, 359-375, 1998.
59. Talsma H, Cherng JY, Van de Wetering P, Crommelin DJA, and Hennink WE. Poly(2-(dimethylaminoethyl methacrylate) nanoparticles for gene transfection. In: *Future Strategies for Drug Delivery with Particulate Systems*, J.E. Diederichs and R.H. Müller, medpharm. GmbH Scientific publishers, Stuttgart, Germany, 177-183, 1998.
60. Crommelin DJA, Hennink WE, and Storm G. Strategies for site specific, time and rate controlled delivery of drugs, genes and antigens. In: *Future Strategies for Drug Delivery with Particulate Systems*, J.E. Diederichs and R.H. Müller, medpharm. GmbH Scientific publishers, Stuttgart, Germany, 127-132, 1998.
61. Wink T, De Beer J, Hennink WE, Bult A, and Van Bennekom WP. Interaction between plasmid DNA and cationic polymers studied by surface plasmon resonance spectrometry. *Anal. Chem.* 71, 801-805, 1999.
62. Franssen O, Van Rooijen RD, De Boer D, Maes RAA, and Hennink WE. Enzymatic degradation of crosslinked dextrans. *Macromolecules* 32, 2896-2903, 1999.
63. Cherng JY, Talsma H, Verrijk R, Crommelin DJA, and Hennink WE. The effect of formulation parameters on the size of poly(2-(dimethylamino)ethyl methacrylate)-plasmid complexes. *Eur. J. Pharm. Biopharm.* 47, 215-224, 1999.
64. Franssen O, Stenakes RJJ, and Hennink WE. Controlled release of a model protein from enzymatically-degrading dextran microspheres. *J. Control. Release* 59, 219-228, 1999.
65. Franssen O, Vandervennet L, Roders P, and Hennink WE. Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. *J.*

- Control. Release 60, 211-221, 1999.
66. Van Es RJJ, Franssen O, Dullens HFJ, Bernsen MR, Bosman F, Hennink WE, and Slootweg FJ. The VX2 carcinoma in the rabbit auricle as an experimental model for the intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheres. *Lab. Anim.* 33, 175-184, 1999.
 67. Hinrichs WLJ, Schuurmans-Nieuwenbroek NME, Van de Wetering P, and Hennink WE. Thermosensitive polymers as carriers for DNA delivery. *J. Control. Release* 60, 249-259, 1999.
 68. Cheng JY, Schuurmans-Nieuwenbroek NME, Jiskoot W, Talsma H, Zuidam NJ, Hennink WE, and Crommelin DJA. Effect of DNA topology on the transfection efficiency of poly(2-(dimethylamino)ethyl methacrylate)-plasmid complexes. *J. Control. Release* 60, 343-353, 1999.
 69. Van de Wetering P, Moret EE, Schuurmans-Nieuwenbroek NME, Van Steenberghe MJ, and Hennink WE. Structure-activity relationships of water-soluble cationic methacrylate/methacrylamide polymers for nonviral gene delivery. *Bioconjugate Chem.* 10, 687-692, 1999.
 70. Mayvis TKL, De Smedt SC, Demester J, and Hennink WE. Rheological monitoring of long-term degrading polymer hydrogels. *J. Rheol.* 43, 933-950 1999.
 71. Stenekes RJH, and Hennink WE. Equilibrium water content of microspheres based on crosslinked dextran. *Int. J. Pharm.* 189, 62-65, 1999.
 72. Arigita C, Zuidam NJ, Crommelin DJA, and Hennink WE. Association and dissociation characteristics of polymer/DNA complexes used for gene delivery. *Pharm. Res.* 16, 1534-1541, 1999.
 73. Van Dijk-Wolthuis WNE, Van de Wetering P, Hinrichs WLJ, Hofmeyer LJJ, Liskamp RMJ, Crommelin DJA, and Hennink WE. A versatile method for the conjugation of proteins and peptides to poly(2-(dimethylamino)ethyl methacrylate). *Bioconjugate Chem.* 10, 589-597, 1999.
 74. Cadée JA, De Korf M, De Groot CJ, Den Otter W, and Hennink WE. Synthesis and characterization of 2-(methacryloyloxy)ethyl-(di)-L-lactate and their application in dextran-based hydrogels. *Polymer* 40, 6877-6881, 1999.
 75. Cheng JY, Talsma H, Crommelin DJA, and Hennink WE. Long term stability of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems. *Pharm. Res.* 16, 1417-1423, 1999.
 76. Den Otter W, Balemans L, Batterman JJ, Bernsen MR, Cadée JA, Dobrowolski Z, Everse LA, Fijzer-Maliszewska L, Gavhumeade R, De Groot JW, De Groot K, Hennink WE, Graham Hill FW, Jurgens-Schulz I, Klein WR, Koten JW, Maas RA, Steenberg P, Stewart R, and Zembala M. Local low-dose IL-2 therapy, Hepato-Gastroenterology 46, 1280-1286, 1999.
 77. Van de Wetering P, Schuurmans-Nieuwenbroek NME, Hennink WE, and Storm G. Comparative transfection studies of human ovarian carcinoma cells in vitro, ex vivo and in vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. *J. Gene Med.* 1, 156-165, 1999.
 78. Stenekes RJH, Franssen O, Van Bommel EM, Crommelin DJA, and Hennink WE. The use of aqueous PEG/dextran phase separation for the preparation of dextran microspheres. *Int. J. Pharm.* 183, 29-32, 1999.
 79. Cheng JY, Van de Wetering P, Talsma H, Crommelin DJA, and Hennink WE. Stabilization of polymer-based gene delivery systems. *Int. J. Pharm.* 183, 25-28 1999.
 80. Den Otter W, Cadée JA, Gavhumeade R, De Groot CJ, Hennink WE, and Stewart R. Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. *Cancer Immunol. Immunother.* 48, 419-420, 1999.
 81. De Jong SJ, Van Dijk-Wolthuis WNE, Kettnes-van den Bosch JJ, and Hennink WE. Stereocomplex formation in enantiomeric lactic acid oligomers. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 26, 691-692, 1999.
 82. Fonseca MJ, Storm G, Hennink WE, Gerritsen WR, and Talsma HJ. Cationic polymeric gene delivery of β -glucuronidase for doxorubicin prodrug therapy. *J. Gene Med.* 1, 404-417, 1999.
 83. Neradovic D, Hinrichs WLJ, Kettnes-van den Bosch JJ, and Hennink WE. Poly(N-isopropylacrylamide) with hydrolyzable lactic acid side groups: a new type of thermosensitive polymer. *Macromol. Rapid Commun.* 20, 577-581, 1999.
 84. Van de Wetering P, Van Steenberghe MJ, Crommelin DJA, and Hennink WE. Copolymers of 2-dimethylaminoethyl methacrylate with ethoxytriethylene glycol methacrylate or N-vinyl-pyrrolidone as gene transfer agents. *J. Control. Release* 64, 193-203, 2000.

85. Stenekes RJH, and Hennink WE. Polymerization kinetics of dextran-bound methacrylate in an aqueous two phase system. *Polymer* 41, 5563-5569, 2000.
86. Cadée JA, Van Luyn MJA, Brouwer LA, Plantinga JA, Van Wachem PB, De Groot CJ, Den Otter W, and Hennink WE. In vivo biocompatibility of dextran-based hydrogels. *J. Biomed. Mater. Res.* 50, 397-404, 2000.
87. De Smedt SC, Demeester J, and Hennink WE. Cationic polymer based gene delivery systems. *Pharm. Res.* 17, 113-126, 2000.
88. Zuidam NJ, Posthuma G, De Vries BT, Crommelin DJA, Hennink WE, and Storm G. Effects of physicochemical characteristics of poly(2-(dimethyl-amino)ethyl methacrylate)-based polyplexes on cellular association and internalization. *J. Drug Target.* 8, 51-66, 2000.
89. De Jong SJ, De Smedt SC, Wahls MWC, Demeester J, Kettenes-van den Bosch JJ, and Hennink WE. Novel self-assembled hydrogels by stereocomplex formation in aqueous solution of enantiomeric lactic acid oligomers grafted to dextran. *Macromolecules* 33, 3680-3686, 2000.
90. Meyvis TKL, De Smedt SC, Demeester J, and Hennink WE. Influence of the degradation mechanism of hydrogels on their elastic and swelling properties during degradation. *Macromolecules* 33, 4717-4725, 2000.
91. Van de Weert M, Van 't Hof R, Van der Weert J, Heeren RM, Posthuma G, Hennink WE, and Crommelin DJA. Lysozyme distribution and conformation in a biodegradable polymer matrix as determined by FTIR techniques. *J. Control. Release* 68, 31-40, 2000.
92. Stenekes RJH, Loeblis AE, Fernandes CM, Crommelin DJA, and Hennink WE. Controlled release of liposomes from biodegradable dextran microspheres: a novel delivery concept. *Pharm. Res.* 17, 690-695, 2000.
93. Hennink WE, Cadée JA, De Jong SJ, Franssen O, Stenekes RJH, Van Nostrum RN, Talma H, and Van Dijk-Wolthuis WNE. Biodegradable hydrogels for the controlled release of pharmaceutical applications. In: *Biomaterials and drug delivery toward new millennium* (Park KD, Kwon IC, Yul N, Jeong SY, Park K. Eds.) Han Rim Won Publishing, 131-147, 2000.
94. Van de Weert M, Hoechstetter J, Hennink WE, and Crommelin DJA. The effect of a water/organic interface on the structural stability of lysozyme. *J. Control. Release* 68, 351-359, 2000.
95. Storm G, Van de Wetering P, Zuidam NJ, Cherng JY, Talma H, Crommelin DJA, and Hennink WE. Methacrylate-based polyplexes as transfection agent. *NATO Sci. Ser., Ser. A* 323 (Targeting of Drugs: Strategies for Gene Constructs and Delivery), 192-199, 2000.
96. Cadée JA, Van Luyn MJA, Brouwer LA, Van Wachem PB, De Groot CJ, Den Otter W, and Hennink WE. In vivo biocompatibility and interleukin-3 release behaviour of dextran-based hydrogels. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 1056-1057, 2000.
97. Van de Weert M, Hennink WE, and Crommelin DJA. Lysozyme structure and stability in poly(lactic-co-glycolic acid) microspheres. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 962-963, 2000.
98. Talma H, Cherng JY, Crommelin DJA, and Hennink WE. Long term stability of gene delivery systems based on poly((2-dimethylamino)ethyl methacrylate)/plasmid complexes. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 826-827, 2000.
99. De Jong SJ, De Smedt SC, Kettenes-van den Bosch JJ, Hennink WE. Hydrogels formed by physical interaction of enantiomeric lactic acid oligomers grafted to dextran. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 680-681, 2000.
100. Neradovic D, Hinrichs WJ, Kettenes-van den Bosch JJ, Van Nostrum CF, and Hennink WE. A new type of thermosensitive polymer: Poly(N-isopropylacrylamide) with hydrolyzable lactic acid ester side groups. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 612-613, 2000.
101. Stenekes RJH, Loeblis AE, Fernandes CM, Crommelin DJA, and Hennink WE. A novel delivery system based on liposomes entrapped in biodegradable dextran microspheres. *Proc. Int. Symp. Controlled Release Bioact. Mater.*, 281-282, 2000.
102. Stenekes RJH, De Smedt SC, Demeester J, Sun G, Zhang Z, and Hennink WE. Pore sizes in hydrated dextran microspheres. *Biomacromolecules* 1, 696-703, 2000.
103. Hennink WE, and Crommelin DJA. Stabilisation and storage of nucleic acids for transformation when not incorporated into viruses. *Eur. Pat. Appl.*, EP 1022340, 2000.
104. Van de Weert M, Hennink WE, and Jiskoot W. Protein instability in poly(lactic-co-

- glycolic acid) microparticles. *Pharm. Res.* 17, 1159-1167, 2000.
105. Hennink WE., Van Nostrum CF, and De Jong SJ. Stereocomplex hydrogels. *PCT Int. Appl. WO 0048576 A1*, 2000.
 106. Bos GW, Trullas-Jimeno A, Jiskoot W, Crommelin DJA, and Hennink WE. Sterilization of poly(dimethylamino)ethyl methacrylate-based gene transfer complexes. *Int. J. Pharm.* 211, 79-88, 2000.
 107. De Jong SJ, Ruiz-Arias E, Rijkers DTS, van Nostrum CF, Kettenes-van den Bosch JJ, and Hennink WE. New insights into the hydrolytic degradation of poly(lactic acid): Participation of the alcohol terminus. *Polymer* 42, 2795-2802, 2001.
 108. Steendam R, Van Steenberghe MJ, Hennink WE, Frijlink HW, and Lerk CF. Effect of molecular weight and glass transition on relaxation and release behaviour of poly(di-lactic acid) tablets. *J. Control. Release* 70, 71-82, 2001.
 109. Hennink WE, Huijrichs WLJ, and Mulders-Neradovic D. Temperature sensitive polymers. *Eur. Pat. Appl. EP 1072617*, 2001.
 110. Hennink WE, Cherng JY, Jiskoot W, Talsma H, and Crommelin DJA. Pharmaceutical aspects of polymer-based non-viral gene delivery systems: experience with p(DMAEMA)-pCMV-lacZ polyplexes. *S.T.P. Pharma Sciences* 11, 11-19, 2001.
 111. Stenekes RJH, Loebis AE, Fernandes CM, Crommelin DJA, and Hennink WE. Degradable dextran microspheres for the controlled release of liposomes. *Int. J. Pharm.* 214, 17-20, 2001.
 112. Verbaan FJ, Oussoren O, Van Dam IM, Takakura Y, Hashida M, Crommelin DJA, Hennink WE, and Storm G. The fate of poly(2-dimethyl amino ethyl) methacrylate-based polyplexes after intravenous administration. *Int. J. Pharm.* 214, 99-101, 2001.
 113. De Jong SJ, Van Berdenbrugh B, Van Nostrum CF, Kettenes-van den Bosch JJ, and Hennink WE. Physically crosslinked dextran hydrogels by stereocomplex formation of lactic acid oligomers: degradation and protein release behavior. *J. Control. Release* 71, 261-275, 2001.
 114. De Jong SJ, De Smedt SC, Demester J, Van Nostrum CF, Kettenes-van den Bosch JJ, and Hennink WE. Biodegradable hydrogels based on stereocomplex formation between lactic acid oligomers grafted to dextran. *J. Control. Release* 72, 47-56, 2001.
 115. Yilmaz G, Jongboom ROJ, Feil K, and Hennink WE. Encapsulation of sunflower oil in starch matrices via extrusion: effect of the interfacial properties and processing conditions on the formation of dispersed phase morphologies. *Carbohydr. Polym.* 45, 403-410, 2001.
 116. De Groot CJ, Van Luyn MJA, Van Dijk-Wolthuis WNE, Cadée JA, Plantinga JA, Den Otter W, and Hennink WE. In vitro biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts. *Biomaterials* 22, 1197-1203, 2001.
 117. Stenekes RJH, Talsma H, and Hennink WE. Formation of dextran hydrogels by crystallization. *Biomaterials* 22, 1891-1898, 2001.
 118. Nijssen J, Rook D, Brandt C, Meijer R, Dullens H, Zonnenberg B, De Klerk J, Van Rijk P, Hennink WE, Van het Schip AD. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. *Eur. J. Nucl. Med.* 28, 743-749, 2001.
 119. Cadée JA, Brouwer LA, Den Otter W, Hennink WE, and Van Luyn MJA. A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic) acid after subcutaneous injection in rats. *J. Biomed. Mater. Res.* 56, 600-609, 2001.
 120. Mastroianni E, Kapel RHG, Eggenhuisen MH, Roholl PJM, Crommelin DJA, Hennink WE, and Storm G. Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. *Cancer Gene Ther.* 8, 405-413, 2001.
 121. Nijssen JWF, Van Steenberghe MJ, Kooijman H, Talsma H, Kroon-Batenburg LMI, Van de Weert M, Van Rijk PP, De Witte A, Van het Schip AD, and Hennink WE. Characterization of poly(L-lactic acid) microspheres loaded with holmium acetylacetonate. *Biomaterials* 22, 3073-3081, 2001.
 122. Hennink WE, Cadée JA, De Jong SJ, Franssen RJH, Talsma H, and Van Dijk-Wolthuis WNE. Molecular design of degradable dextran hydrogels for the controlled release of proteins. In: *Biomedical Polymers and Polymer Therapeutics*. Edited by Emo Chiellini, Junzo Sunamoto, Claudio Migliarese, Raphael M. Otenbrite and Daniel Cohn. Kluwer Academic/Plenum Publishers, New York, 3-16, 2001.
 123. Hennink WE, Van de Wetering F, Storm G, and Crommelin DJA. Gene delivery with water-soluble cationic methacrylate/methacrylamide polymers. In: *Proceedings of the 6th International Symposium on Adjuvants for Agrochemicals*. Edited by Hans de

- Ruiter. 595-607, 2001.
124. Cadée JA, Van Steenberghe MJ, Vershuis C, Heck AJR, Underberg WJM, Den Otter W, Jiskoot W, and Hennink WE. Oxidation of interleukin-2 by potassium peroxodisulfate. *Pharm. Res.* 18, 1461-1467, 2001.
125. Hennink WE, and Franssen O. Preparation of microspheres containing colloidal systems. *PCT Int. Appl.*, WO 0160339 A2 20010823, 2001.
126. Bos GW, Crommelin DJA, and Hennink WE. Water-soluble cationic methacrylate polymers for nonviral gene delivery. *Methods Mol. Med.*, 65, 35-60, 2001.
127. Neradovic D, Van Nostrum CF, and Hennink WE. Thermoresponsive polymeric micelles with controlled instability based on hydrolytically sensitive N-isopropylacrylamide copolymers. *Macromolecules* 34, 7589-7591, 2001.
128. Van de Weert M, Haris PI, Hennink WE, and Crommelin DJA. Fourier transform infrared spectrometric analysis of protein conformation: effect of the sampling method and stress factors. *Anal. Biochem.* 297, 160-169, 2001.
129. Bos GW, Verrijk R, Franssen O, Bezemer JM, Hennink WE, and Crommelin DJA. Hydrogels for the controlled release of pharmaceutical proteins. *Pharmaceutical Technology* 25, 110-120, 2001.
130. Meyvis TKL, De Smedt SC, Stubbe B, Hennink WE, and Demeester J. On the release of proteins from degrading dextran methacrylate hydrogels and the correlation with rheologic properties of the hydrogels. *Pharm. Res.* 18, 1593-1599, 2001.
131. Bos GW, Verrijk R, Franssen O, Bezemer JM, Hennink WE, and Crommelin DJA. Hydrogels for the controlled release of pharmaceutical proteins. *Biopharm Europe* 13, 64-74, 2001.
132. Van Es RJJ, Nijssen FW, Dullens HFJ, Kicken M, Van der Bilt A, Hennink WE, Kollé R, and Slootweg PJ. Tumour embolization of the Vx2 rabbit head and neck cancer model with dextran hydrogel and holmium-poly(L-lactic acid) microspheres: a radionuclide and histological pilot study. *J. Cranio-MaxilloFac. Surg.* 29, 289-297, 2001.
133. Crommelin DJA, Hennink WE and Storm G. Drug targeting systems: fundamental and applications to paracenteral drug delivery. In: *Drug Delivery and Applications to Parenteral Drug Delivery*. Edited by: A.M. Hillery, A.W. Lloyd and J. Swarbrick. Page 117-144, 2001.
134. Storm G, Mastrobattista E, Verbaan FI, Crommelin DJA, and Hennink WE. Design of methacrylate-based polyplexes for tumor targeting. *Gene Ther. Mol. Biol.* 6, 143-148, 2001.
135. Hennink WE, and Van Nostrum CF. Novel crosslinking methods to design hydrogels. *Adv. Drug Del. Rev.* 54, 13-36, 2002.
136. Cadée JA, De Groot CJ, Jiskoot W, Den Otter W, and Hennink WE. Release of recombinant human interleukin-2 from dextran-based hydrogels. *J. Control. Release* 78, 1-13, 2002.
137. Nijssen JWF, Van het Schip AD, Hennink WE, Rook DW, Van Rijk PP, and De Klerk JMH. Advances in nuclear oncology: Microspheres for internal radionuclide therapy of liver tumours. *Curr. Med. Chem.* 9, 73-82, 2002.
138. De Groot CJ, Cadée JA, Kolen JW, Hennink WE, and Den Otter W. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model. *Int. J. Cancer* 98, 134-140, 2002.
139. Nijssen JWF, Van het Schip AD, Van Steenberghe MJ, Zielhuis SW, Kroon-Batenburg LMI, Van de Weert M, Van Rijk PP, and Hennink WE. Influence of neutron irradiation on holmium acetylacetonate loaded poly(L-lactic acid) microspheres. *Biomaterials* 23, 1831-1839, 2002.
140. Stubbe BG, Braeckmans K, Horkay F, Hennink WE, De Smedt SC, and Demeester J. Swelling pressure observations on degrading dex-HEMA hydrogels. *Macromolecules* 35, 2501-2505, 2002.
141. Yilmaz G, Oengen G, Jongboom ROJ, Feil H, Van Dijk C, and Hennink WE. Modulated release of a volatile compound from starch matrices via enzymatically controlled degradation. *Biomacromolecules* 3, 305-311, 2002.
142. De Jong SJ, Van Nostrum CF, Kroon-Batenburg LMI, Kettenes-van den Bosch JJ, and Hennink WE. Oligolactate-grafted dextran hydrogels: detection of stereocomplex crosslinks by X-ray diffraction. *J. Appl. Polym. Sci.* 86, 289-293, 2002.
143. Meyvis TKL, Stubbe BG, Van Steenberghe MJ, Hennink WE, De Smedt SC, and Demeester J. A comparison between the use of dynamic mechanical analysis and oscillatory shear rheometry for the characterisation of hydrogels. *Int. J. Pharm.* 244, 163-168, 2002.

144. Van de Weert M, Van Steenberghe MJ, Cleland JL, Heller J, Hennink WE, and Crommelin DJA. Semisolid, self-catalyzed poly(ortho ester)s as controlled-release systems: protein release and protein stability issues. *J. Pharm. Sci.* 91, 1065-1074, 2002.
145. Van de Weert M, van Dijkhuizen-Radersma R, Bezemer JM, Hennink WE, and Crommelin DJA. Reversible aggregation of lysozymes in a biodegradable amphiphilic multiblock copolymer. *Eur. J. Pharm. Biopharm.* 54, 89-93, 2002.
146. Metselaar JM, Hennink WE, De Vringer T, De Boer LWT, Oussoren C, Storm G, and Bruin P. Lipid-polymer conjugate compositions for colloidal carriers. *PCT Int. Appl. A1* 20021212, 2002.
147. Arigita C, Kersten GFA, Hazendonk T, Hennink WE, Crommelin DJA, Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. *Vaccine* 21, 950-960, 2003.
148. Crommelin DJA, Storm G, Jiskoot W, Steneker R, Mastrobattista E, and Hennink WE. Nanotechnological approaches for the delivery of macromolecules. *J. Control. Release* 87, 81-88, 2003.
149. Van Steenis JH, Van Maarseveen EM, Verbaan FJ, Verrijck R, Crommelin DJA, Storm G, and Hennink WE. Preparation and characterization of folate-targeted PEG-coated pDMAEMA-based polyplexes. *J. Control. Release* 87, 167-176, 2003.
150. Luten J, Van Steenis JH, Van Someren R, Kemmink J, Schuurmans-Nieuwenbroek NME, Koning GA, Crommelin DJA, Van Nostrum CF, and Hennink WE. Water-soluble biodegradable cationic polyphosphazenes for gene delivery. *J. Control. Release* 89, 483-497, 2003.
151. Stubbe BG, Horkay F, Amsden B, Hennink WE, De Smedt SC, and Demeester J. Tailoring the swelling pressure of degrading dextran hydroxyethyl methacrylate hydrogels. *Biomacromolecules* 4, 691-695, 2003.
152. Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJA, Van de Winkel JGJ, Van Vugt MJ, Kersten GFA, and Jiskoot W. Liposomal meningococcal B vaccination: Role of dendritic cell targeting in the development of a protective immune response. *Infect. Immun.* 71, 5210-5218, 2003.
153. Leemhuis M, Van Steenis JH, Van Uxem MJ, Van Nostrum CF, and Hennink WE. A versatile route to functionalized dilactones as monomers for the synthesis of poly(alpha-hydroxy) acids. *Eur. J. Org. Chem.* 17, 3344-3349, 2003.
154. Neradovic D, Van Steenberghe MJ, Vansteelandt L, Meijer YJ, Van Nostrum CF, and Hennink WE. Degradation mechanism and kinetics of thermosensitive polyacrylamides containing lactic acid side chains. *Macromolecules* 36, 7491-7498, 2003.
155. Van Nostrum CF, De Jong SJ, Kettenes-van den Bosch JJ, Hennink WE. Hydrogels by stereocomplex formation and their use as drug delivery matrices. *Advances in Controlled Drug Delivery: Science, Technology, and Products. ACS Symposium Series* 846, 129-141, 2003.
156. Crommelin DJA, Storm G, Verrijck R, De Leede L, Jiskoot W, and Hennink WE. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. *Int. J. Pharm.*, 266, 3-16, 2003.
157. Koten JW, Van Luyk MJA, Cadée JA, Bouwer L, Hennink WE, Bijleveld C, and Den Oter W. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. *Cytokine* 24, 57-66, 2003.
158. Metselaar JM, Bruin P, De Boer LWT, De Vringer T, Snel C, Oussoren C, Wauben MHM, Crommelin DJA, Storm G, and Hennink WE. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. *Bioconjugate Chem.* 14, 1156-1164, 2003.
159. Metz B, Jiskoot W, Hennink WE, Crommelin DJA, and Kersten GFA. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. *Vaccine* 21, 156-167, 2003.
160. Verbaan F, Van Dam I, Takakura Y, Hashida M, Hennink WE, Storm G, and Oussoren C. Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. *Eur. J. Pharm. Sciences* 20, 419-427, 2003.
161. Funteloff AM, Van Nostrum CF, Janssen AFCA, Fens MHAM, Crommelin DJA, and Hennink WE. Polymer side-chain degradation as a tool to control the destabilization of polyplexes. *Pharm. Res.* 21, 170-176, 2004.
162. Verbaan FJ, Oussoren C, Snel CJ, Crommelin DJA, Hennink WE, and Storm G. Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes

- mediates prolonged circulation and tumor targeting in mice. *J. Gene Med.* 6, 64-75, 2004.
163. Funhoff AM, Van Nostrum CF, Koning GA, Schuurmans-Nieuwenbroek NME, Crommelin DJA, and Hennink WE. Endosomal escape of polymeric gene delivery complexes is not always enhanced by polymers buffering at low pH. *Biomacromolecules* 5, 32-39, 2004.
 164. Nenadovic D, Soga O, Van Nostrum CF, and Hennink WE. The effect of the processing and formulation parameters on the size of nanoparticles based on block copolymers of poly(ethylene glycol) and poly(*N*-isopropylacrylamide) with and without hydrolytically sensitive groups. *Biomaterials* 25, 2409-2418, 2004.
 165. Arigita C, Jiskoot W, Westdijk J, Van Ingen C, Hennink WE, Crommelin DJA, and Kersten GFA. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. *Vaccine* 22, 629-642, 2004.
 166. Arigita C, Van den Berg J, Wensink K, Van Steenberghe MJ, Hennink WE, Crommelin DJA, Kersten GFA, and Jiskoot W. Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres. *European Journal of Pharmaceutical Sciences* 21, 131-141, 2004.
 167. Meiz B, Kersten GF, Hoogerhout P, Timmermans HA, De Jong A, Meiring H, Ten Hove J, Hennink WE, Crommelin DJA, and Jiskoot W. Identification of formaldehyde-induced modifications in proteins. Reactions with model peptides. *J. Biol. Chem.* 279, 6235-6243, 2004.
 168. Bos GW, Jacobs JIL, Koten JW, Van Tomme S, Veldhuis Th, Van Nostrum CF, Den Otter W, and Hennink WE. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 delivery. *Bur. J. Pharm. Sciences* 21, 561-567, 2004.
 169. Yilmaz G, Jongboom ROJ, Feil H, Van Dijk C, and Hennink WE. Permeation of volatile compounds through starch films. *Biomacromolecules* 5, 650-656, 2004.
 170. Van Nostrum CF, Veldhuis TFI, Bos GW, and Hennink WE. Tuning the degradation rate of poly(2-hydroxypropyl methacrylamide)-graft-oligo(lactic acid) stereocomplex hydrogels. *Macromolecules* 37, 2113-2188, 2004.
 171. Hennink WE, Van Steenis JR, and Van Nostrum CF. Fast degradable polymers. In: *Reflexive Polymers and Hydrogels. Understanding and designing fast responsive polymeric system*. Ed: Yui N, Mirony RJ, and Park K. CRC Press. Page 401-423, 2004.
 172. Soga O, Van Nostrum CF, and Hennink WE. Poly(*N*-(2-hydroxypropyl) methacrylamide mono/di lactate): a new class of biodegradable polymers with tuneable thermosensitivity. *Biomacromolecules* 5, 818-821, 2004.
 173. Hennink WE, de Jong SJ, Bos GW, Veldhuis TFI, and Van Nostrum CF. Biodegradable dextran hydrogels crosslinked by stereocomplex formation for the controlled release of pharmaceutical proteins. *Int. J. Pharm.* 277, 99-104, 2004.
 174. Verbaan FJ, Bos GW, Oussoren C, Woodle MC, Hennink WE, and Storm G. A comparative study of different cationic transfection agents for in vivo gene delivery after intravenous administration. *J. Drug Del. Sci. Tech.* 14, 1-7, 2004.
 175. Van Nostrum CF, Veldhuis TFI, Bos GW, and Hennink WE. Hydrolytic degradation of oligo(lactic acid): a kinetic and mechanistic study. *Polymer* 45, 6779-6787, 2004.
 176. Soga O, Van Nostrum CF, Ramzi A, Visser T, Soulimani F, Frederik PM, Bomans PHH, and Hennink WE. Physicochemical characterization of thermosensitive and degradable polymeric micelles. *Langmuir* 20, 9388-9395, 2004.
 177. Stubbe BG, Hennink WE, De Smedt SC, and Demeester J. On the swelling pressure of hydrogels that degrade through different mechanisms. *Macromolecules* 37, 8739-8744, 2004.
 178. Bos GW, Kaneilios T, Crommelin DJA, Hennink WE, and Howard CR. Cationic polymers that enhance the performance of HbsAg DNA in vivo. *Vaccine* 23, 460-469, 2004.
 179. Funhoff AM, Van Nostrum CF, Lok MC, Frez MM, Crommelin DJA, and Hennink WE. Poly(3-guanidinopropyl methacrylate): a novel cationic polymer for gene delivery. *Bioconjugate Chemistry* 15, 1212-1220, 2004.
 180. Verbaan FJ, Crommelin DJA, Hennink WE, and Storm G. Poly(2-dimethylamino)ethyl methacrylate)-based polymers for the delivery of genes in vitro and in vivo. In: *Polymeric Gene Delivery*. Ed. Majji MM. CRC Press, page 107-132, 2004.
 181. Vermonde T, Van Steenberghe MJ, Besseling NAN, Marcelis ATM, Hennink WE, Sudholter EJR, and Cohen Stuart MA. Linear Rheology of water-soluble reversible

- neodymium(III) coordination polymers. *Journal of the American Chemical Society* 126, 15802-15808, 2004.
182. Van Tongue SR, Van Steenberghe MJ, De Smedt SC, Van Nostrum CF, and Hennink WE. Self-gelling hydrogels based on oppositely charged dextran microspheres. *Biomaterials* 26, 2129-2135, 2005.
183. Funhoff AM, Van Nostrum CF, Lok MC, Kruijtz JAW, Crommelin DJA, and Hennink WE. Cationic polymethacrylates with covalently linked membrane destabilizing peptides as gene delivery vectors. *Journal of Controlled Release* 101, 233-246, 2005.
184. Chung JT, Vlught-Wensink KDF, Hennink WE, and Zhang Z. Effect of polymerization conditions on the network properties of Dax(HEMA) microspheres and macro-hydrogels. *International Journal of Pharmaceutics* 288, 51-61, 2005.
185. Bos GW, Hennink WE, Brouwer LA, den Otter W, Veldhuis TFI, van Nostrum CF, and Van Luyn MJA. Biocompatibility of *in situ* formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats. *Biomaterials* 26, 3901-3909, 2005.
186. Zielhuis SW, Nijssen JFW, Figueiredo R, Feddes B, Vredenburg AM, Van het Schip AD, and Hennink WE. Surface characteristics of holmium-loaded poly(L-lactic acid) microspheres. *Biomaterials* 26, 925-932, 2005.